Search
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnIt is estimated that the patients with the most severe forms of refractory aGvHD that do not respond to steroid therapy have expected one-year survival rates of only 5% to 30% [L11022]. … In clinical studies, patients treated with remestemcel-L demonstrated an improvement in their aGvHD and improved survival rates at subsequent days following intravenous infusion [L11022].
Omalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigationalOmalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). IgE promotes the release of inflammatory mediators from mast cells and basophils during allergic and inflammatory reacti...
Alvespimycin
go.drugbank.com/drugs/DB12442InvestigationalIt has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent.
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSalsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. … Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
Hexafluronium
go.drugbank.com/drugs/DB00941ApprovedHexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholineste...
Dronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigationalDronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primaril...
Synonyms: N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesPariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801ApprovedPariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase … [L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia.
Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigationalQuizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRomiplostim
go.drugbank.com/drugs/DB05332ApprovedInvestigationalEach subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl.